Clinical trials in Corbeil Essonnes – page 26

3 332 clinical trials in Corbeil Essonnes, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Corbeil Essonnes at a glance

3 332

clinical trials

Research sites1

Quick filters

3 332 trials in Corbeil Essonnes

Open in trial search

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:AZD5335
Sponsor:AstraZeneca AB

Contact Research Centre

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Paclitaxel
Sponsor:Genmab A/S

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Endometrial cancer

Recruiting

A study of ACR-368 and gemcitabine for patients with endometrial cancer

Registered drugNo placebo

A study of ACR-368 and gemcitabine for patients with endometrial cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Acrivon Therapeutics Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Bile duct cancer

Recruiting

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer

Recruiting

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Pericarditis

Recruiting

A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:KPL-387
Sponsor:Kiniksa Pharmaceuticals GmbH

Contact Research Centre

Bronchiectasis

Recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational

France

Participants:18–64 years · 65+ years
Substances:AZD0292
Sponsor:AstraZeneca AB

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational

A study to evaluate the effectiveness and safety of REGN13335 in adults with pulmonary arterial hypertension

Investigational

France

Participants:18–64 years · 65+ years
Substances:Vasigrobart
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Neoplasm

Recruiting

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo

A study of RPTR-1-201 and pembrolizumab in patients with advanced solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Repertoire Immune Medicines Inc.

Contact Research Centre

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Corbeil Essonnes

What the registry says about research in the country

01 Diabetes and Metabolic Disorders

Clinical research focusing on novel treatments for Type 1 and Type 2 Diabetes, particularly investigating therapies like tirzepatide for glycemic control and cardiovascular outcomes in patients with obesity and diabetes.

Glycemic Control Studies
Cardiovascular Risk Management
Weight Management Therapies

02 Hematologic Malignancies

Groundbreaking trials in Multiple Myeloma treatment, evaluating combinations of targeted therapies including elranatamab, lenalidomide, and daratumumab for newly diagnosed and relapsed cases.

Novel Drug Combinations
Maintenance Therapy Optimization
Minimal Residual Disease Studies

03 Inflammatory and Autoimmune Conditions

Research examining innovative treatments for Immune Thrombocytopenia, Polymyalgia Rheumatica, and Lupus Nephritis, focusing on targeted therapies and steroid-sparing approaches.

Immunotherapy Development
Alternative Treatment Strategies
Disease Management Protocols

Back to France All countries